Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578464 | 1.00 | MCHR1 (0.48) | MCHR1KCNH2RORCHTR2AHTR2C | |
| SCHEMBL578509 | 1.00 | MCHR1 (0.48) | MCHR1KCNH2RORCHTR2AHTR2C | |
| SCHEMBL22837830 | 0.89 | HTR2A (0.43) | MCHR1KCNH2RORCHTR2AHTR2C | |
| SCHEMBL12499527 | 0.85 | HRH3 (0.37) | MCHR1KCNH2RORCHTR2AHTR2C | |
| SCHEMBL14450799 | 0.84 | MCHR1 (0.49) | MCHR1KCNH2RORCMAP4K4 | |
| SCHEMBL14924424 | 0.84 | MCHR1 (0.49) | MCHR1KCNH2RORCMAP4K4 | |
| SCHEMBL27389111 | 0.84 | MCHR1 (0.49) | MCHR1KCNH2RORCMAP4K4 | |
| SCHEMBL34469712 | 0.84 | MCHR1 (0.49) | MCHR1KCNH2RORCMAP4K4 | |
| SCHEMBL24681150 | 0.83 | MCHR1 (0.59) | MCHR1KCNH2RORC | |
| SCHEMBL188110 | 0.83 | MCHR1 (0.48) | MCHR1KCNH2RORCMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47731-E1 | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK (CA) | 2019-11-19 | — | — | US | disclosed |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2019-07-23 | — | — | US | disclosed |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-04 | — | — | US | disclosed |
| US-9907800-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2018-03-06 | — | — | US | disclosed |
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2016-02-18 | — | — | US | disclosed |
| US-9139563-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2015-09-22 | — | — | US | disclosed |
| US-8999968-B2 | Kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2015-04-07 | — | — | US | disclosed |
| EP-2417127-B1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK (CA) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045822-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20140045838-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIV HEALTH NETWORK (CA) | 2014-02-13 | — | — | US | disclosed |
| US-8481525-B2 | Kinase inhibitors and method of treating cancer with same | UNIVERSITY OF HEALTH NETWORK (CA) | 2013-07-09 | — | — | US | disclosed |
| US-8481533-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-07-09 | — | — | US | disclosed |
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2012-10-18 | — | — | US | disclosed |
| US-8263596-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2012-09-11 | — | — | US | disclosed |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORKS (CA) | 2012-06-14 | — | — | US | disclosed |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | MCHR1 4497/4885KCNH2 2512/4885RORC 2241/4885 |
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | MCHR1 4497/4885KCNH2 2512/4885RORC 2241/4885 |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | MCHR1 4229/4885KCNH2 2673/4885RORC 2257/4885 |
| US-20140045838-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | MCHR1 4497/4885KCNH2 2512/4885RORC 2241/4885 |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | MCHR1 4497/4885KCNH2 2512/4885RORC 2241/4885 |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | MAP3K6, MAP3K5, MAP3K19 | MCHR1 4497/4885KCNH2 2512/4885RORC 2241/4885 |
| US-20140045822-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | MCHR1 4229/4885KCNH2 2673/4885RORC 2257/4885 |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | MCHR1 4497/4885KCNH2 2512/4885RORC 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.